RxDoctor Payments DataLook up a doctor →

Oscar Florendo, MD

Pain Medicine · High Point, NCNPI 1174565568

Payments from drug & device makers

$8,930in general payments, 2019–2025

Across 537 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lilly USA, LLC$1K
  • Amgen$717
  • Novo Nordisk$579
  • AstraZeneca$475
  • Johnson & Johnson$393
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,76198%
  • Education$1682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,930 in reported general payments places this provider in the 70th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$42,576
Medicare patients
74
Services billed
1,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast17$91,332
XifaxanRifaximin27$88,573
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$68,863
VraylarCariprazine Hcl28$40,142
OzempicSemaglutide26$39,967
VascepaIcosapent Ethyl44$37,747
MounjaroTirzepatide28$37,297
TrulicityDulaglutide24$36,949
EliquisApixaban38$31,016
UbrelvyUbrogepant18$30,629
Repatha SureclickEvolocumab32$24,806
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$21,088
LinzessLinaclotide16$20,762
EntrestoSacubitril/Valsartan17$17,617
JanuviaSitagliptin Phosphate11$15,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Ubrelvy, Linzess, Synthroid$2,581$92,85675 claims
AmgenOtezla$717$91,33217 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$290$88,57327 claims
Lilly USA, LLCMounjaro, Trulicity$1,032$74,24552 claims
GSKTrelegy Ellipta$268$68,86367 claims
Novo NordiskOzempic$579$39,96726 claims
PfizerEliquis, Paxlovid$138$32,35653 claims
AstraZenecaBreztri Aerosphere$475$21,08825 claims
NovartisEntresto$134$17,61717 claims
MerckJanuvia$106$15,59611 claims
Astellas Pharma US IncMyrbetriq$179$7,49413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in High Point

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →